HC Wainwright Reiterates “Buy” Rating for OPKO Health (NASDAQ:OPK)

HC Wainwright restated their buy rating on shares of OPKO Health (NASDAQ:OPKFree Report) in a report published on Wednesday, Benzinga reports. The firm currently has a $3.00 price objective on the biotechnology company’s stock.

A number of other brokerages have also weighed in on OPK. StockNews.com lowered OPKO Health from a hold rating to a sell rating in a research report on Friday, March 1st. Barrington Research restated an outperform rating and set a $1.50 price objective on shares of OPKO Health in a research report on Monday. Finally, Piper Sandler restated an overweight rating and set a $5.00 price objective on shares of OPKO Health in a research report on Monday.

Get Our Latest Stock Report on OPK

OPKO Health Stock Performance

Shares of OPK stock opened at $1.35 on Wednesday. OPKO Health has a 52-week low of $0.85 and a 52-week high of $2.24. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55. The firm has a market capitalization of $940.94 million, a PE ratio of -5.40 and a beta of 1.82. The stock has a fifty day simple moving average of $1.01 and a two-hundred day simple moving average of $1.26.

OPKO Health (NASDAQ:OPKGet Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business had revenue of $181.90 million during the quarter, compared to analyst estimates of $177.53 million. During the same quarter in the prior year, the business posted ($0.11) EPS. OPKO Health’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, analysts predict that OPKO Health will post -0.33 EPS for the current fiscal year.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 1,500,000 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was purchased at an average price of $0.90 per share, with a total value of $1,350,000.00. Following the acquisition, the chief executive officer now owns 203,456,694 shares in the company, valued at $183,111,024.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other OPKO Health news, Director Richard M. Krasno purchased 30,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average price of $0.99 per share, with a total value of $29,700.00. Following the acquisition, the director now owns 103,333 shares in the company, valued at $102,299.67. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Phillip Md Et Al Frost acquired 1,500,000 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was purchased at an average cost of $0.90 per share, with a total value of $1,350,000.00. Following the purchase, the chief executive officer now owns 203,456,694 shares of the company’s stock, valued at $183,111,024.60. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 8,993,015 shares of company stock valued at $8,479,069. Insiders own 47.26% of the company’s stock.

Institutional Trading of OPKO Health

Institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its stake in OPKO Health by 300.4% in the third quarter. Invesco Ltd. now owns 5,164,180 shares of the biotechnology company’s stock worth $8,263,000 after purchasing an additional 3,874,519 shares during the last quarter. EP Wealth Advisors LLC lifted its stake in OPKO Health by 140.3% in the third quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 18,041 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in OPKO Health by 7.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 5,549,946 shares of the biotechnology company’s stock worth $8,880,000 after purchasing an additional 405,106 shares during the last quarter. Barclays PLC lifted its stake in OPKO Health by 17.4% in the third quarter. Barclays PLC now owns 188,421 shares of the biotechnology company’s stock worth $302,000 after purchasing an additional 27,946 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its stake in OPKO Health by 1,509.6% in the third quarter. Public Employees Retirement System of Ohio now owns 144,928 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 135,924 shares during the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Featured Articles

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.